Cnbx Pharmaceuticals Inc (CNBK) Return on Equity ROE from the third quarter 2026 to third quarter 2025 and annually, average high and low, overall ranking from May 31 2026 to May 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Cnbx Pharmaceuticals Inc   (CNBK)

Cnbx Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Cnbx Pharmaceuticals Inc in the third quarter 2026?
Due to the lack of equity, it was not possible to calculate Cnbx Pharmaceuticals Inc 's return on equity (ROE) in its third quarter 2026

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (May 31 2026)
III. Quarter		 (Feb 28 2026)
II. Quarter		 (Nov 30 2025)
I. Quarter		 (Aug 31 2025)
IV. Quarter		 (May 31 2025)
III. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions 0 0 0 0 0
Return On Equity (TTM) - - - - -
CNBK's Total Ranking # # # # #
Equity (TTM) in Millions -3 -3 -3 -2 -3
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to CNBK Management Effectiveness >> CNBK's 5 Years Annual ROE >> Compare CNBK ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





CNBK Annual Return On Equity (Aug 31 2025)
2025		 (Aug 31 2024)
2024		 (Aug 31 2023)
2023		 (Aug 31 2022)
2022		 (Aug 31 2021)
2021
Total Equity in Millions -2 -2 -2 -2 2
Y / Y Equity Change - - - - 2.34 %
Net Income in Millions 0 -1 -4 -4 -3
Y / Y Net Income Change - - - - -
Return On Equity - - - - -176.89 %

Back to CNBK Management Effectiveness >> CNBK's 5 Years Annual ROE >> Compare CNBK ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CNBK's' Return on Equity at Yahoo Finance
CNBK's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CNBK's Competitors
Subscribers only: Roe for Cnbx Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for CNBK's Customers




Companies with similar Return On Equity at May 31 2026, within Healthcare Sector ROE
Nrc Health  48.29 %
Concentra Group Holdings Parent Inc   48.13 %
Bristol myers Squibb Company  46.65 %
Agilent Technologies inc   41.99 %
Eton Pharmaceuticals Inc   40.13 %
Adma Biologics Inc   39.59 %
Dexcom Inc   36.25 %
Transmedics Group Inc   33.37 %
Arcutis Biotherapeutics Inc   32.92 %
Caredx Inc   32.81 %
Zevra Therapeutics Inc   32.56 %
Acadia Pharmaceuticals Inc   32.39 %
Pro dex Inc   31.96 %
Protalix Biotherapeutics inc   31.61 %
Illumina Inc   31.08 %
Innoviva Inc   30.03 %
Phibro Animal Health Corporation  29.66 %
Chemed Corporation  29.45 %
Solventum Corporation  28.96 %
Pacs Group Inc   27.00 %
Sotera Health Company  26.75 %
Insulet Corporation  26.69 %
Bioventus Inc   25.96 %
Johnson and Johnson  25.74 %
Encompass Health Corporation  25.52 %
Resmed Inc   24.21 %
Healthcare Services Group Inc   24.12 %
Electromed Inc   23.65 %
Iradimed Corporation  23.45 %
Vertex Pharmaceuticals Inc  23.31 %

Date modified: 2026-07-01T13:22:21+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.